• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Paranovus Entertainment Technology Ltd.

    1/14/25 4:45:54 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    S-8 1 pavs_s8.htm FORM S-8 pavs_s8.htm

     As filed with the Securities and Exchange Commission on January 14, 2025

    Registration No. 333- 

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LIMITED

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands

     

    Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

     

    250 Park Avenue, 7th Floor

     New York, NY

     

    10177

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Paranovus Entertainment Technology Limited

    2024 Equity Incentive Plan

    (Full Title of the Plan)

     

     Xiaoyue Zhang

    250 Park Avenue

    7th Floor

    New York, NY 10177

    516-951-9074

     

    With copies to:

     

    Joan Wu, Esq.

    Hunter Taubman Fischer & Li LLC

    950 Third Avenue, 19th Floor

    New York, NY 10022

    (212) 530-2210

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☐

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Paranovus Entertainment Technology Limited (the “Registrant,” “we,” “us,” “our,” or similar terminology) has prepared this registration statement on Form S-8 (the “Registration Statement”) in accordance with the requirements of General Instruction E to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”) to register an aggregate of  10,008,701 Class A ordinary shares, par value US$0.01 per share (the “Ordinary Shares”), which are reserved for issuance under the Paranovus Entertainment Technology Limited 2024 Equity Incentive Plan (the “Plan”). This Registration Statement is being filed in order to register the Registrant’s Ordinary Shares that may be offered or sold to participants under the Plan, either directly or upon exercise of options or other share-based awards granted under the Plan.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.*

     

    Item 2. Registration Information and Employee Plan Annual Information.*

     

    * The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 (Plan Information and Registration Information and Employee Plan Annual Information) will be sent or given to recipients of the grants under the Plan as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. The Registrant will provide a written statement to participants advising them of the availability without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge, upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b) of the Securities Act, and will include the address and telephone number to which the request is to be directed.

     

     
    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission, including the Registrant. The address for the Commission’s website is “http://www.sec.gov.” The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

    (a)

    The Registrant’s Annual Report on Form 20-F (File No. 001-39098) for the fiscal year ended March 31, 2024 filed with the Commission on August 1, 2024;

     

     

    (b)

    The Registrant’s Current Reports on Form 6-K furnished to the Commission on August 8, 2024, August 13, 2024, and October 3, 2024, respectively; and

     

     

    (c)

    The description of the Registrant’s Ordinary Shares, incorporated by reference in the Registrant’s registration statement on Form 8-A filed (Registration No. 001-39098) with the Commission on October 22, 2019, and any amendment or report filed for the purpose of updating such description.

     

    Except to the extent such information is deemed furnished and not filed pursuant to securities laws and regulations, all documents that we file with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act and, to the extent specifically designated therein, reports on Form 6-K furnished by the Registrant to the Commission, in each case, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement (that indicates that all securities offered under this Registration Statement have been sold or that deregisters all securities then remaining unsold) shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

     

    Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     
    2

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Our amended and restated memorandum and articles of association provide that our current and former directors and officers will be indemnified out of our assets against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual fraud or willful default. In addition, our memorandum and articles of association provide that our directors will not be personally liable for monetary damages to us for breaches of their fiduciary duty as directors, unless their liability arises out of actual fraud or willful default.

     

    We have entered into agreements with our directors and officers to provide contractual indemnification in addition to the indemnification provided in our memorandum and articles of association. We intend to purchase a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify the directors and officers.

     

    These provisions may discourage shareholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

     
    3

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The Exhibits listed on the accompanying Exhibit Index are filed as a part of, or incorporated by reference into, this Registration Statement. (See Exhibit Index below).

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to that information in the Registration Statement

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement;

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for the purposes of determining liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be in the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     
    4

     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

     

    Description of Exhibit

     

     

     

    4.1*

     

    Description of Share Capital

    5.1**

     

    Opinion of Campbells LLP

    23.1**

     

    Consent of Enrome LLP, Independent Registered Public Accounting Firm

    23.2**

     

    Consent of TPS Thayer, LLC, Independent Registered Public Accounting Firm

    23.3**

     

    Consent of Campbells LLP (included in Exhibits 5.1)

    24.1**

     

    Powers of Attorney (included on the signature page of this Registration Statement)

    99.1**

     

    Paranovus Entertainment Technology Limited 2024 Equity Incentive Plan

    107**

     

    Filing Fee Table

     

    *

    Incorporated herein by reference to Exhibit 2.2 of our Annual Report on Form 20-F (File No. 001-39098) filed with the Commission on August 1, 2024.

    **

    Filed herewith.

     

     
    5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in New York on January 14, 2025.

     

    Paranovus Entertainment Technology Limited

     

     

     

     

     

     

    By:

    /s/ Xiaoyue Zhang

     

     

    Name:

    Xiaoyue Zhang

     

     

    Title:

    Chief Executive Officer

     

     

    Power of Attorney

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Xiaoyue Zhang, as his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement (including post-effective amendments and registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933 as amended) and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the following persons in the capacities and on the dates indicated have signed this Registration Statement on Form S-8.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Xiaoyue Zhang

     

    Chief Executive Officer and Director

     

    January 14, 2025

    Xiaoyue Zhang

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Ling Guo

     

    Chief Financial Officer

     

    January 14, 2025

    Ling Guo

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ Minzhu Xu

     

    Chairperson

     

    January 14, 2025

    Minzhu Xu

     

     

     

     

     

     

     

     

     

    /s/ Alex Lightman

     

    Director

     

    January 14, 2025

    Alex Lightman

     

     

     

     

     

     

     

     

     

    /s/ George Yijian Xu

     

    Director

     

    January 14, 2025

    George Yijian Xu

     

     

     

     

     

     

     

     

     

    /s/ David Sean Lu

     

    Director

     

    January 14, 2025

    David Sean Lu

     

     

     

     

     

     
    6

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the Securities Act, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this registration statement in New York on January 14, 2025.

     

    Authorized U.S. Representative

     

     

     

    Xiaoyue Zhang

     

     

     

     

     

     

    By:

    /s/ Xiaoyue Zhang

     

     

    Name:

    Xiaoyue Zhang

     

     

    Title:

    Chief Executive Officer

     

     

     
    7

     

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    1/22/26 5:25:13 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    1/13/26 4:15:52 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/5/25 8:31:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care